Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Brain Behav Immun. 2021 Jan 7;93:80–95. doi: 10.1016/j.bbi.2020.12.016

Figure 2. Repeated systemic administration of the TLR2/TLR4 antagonist (+)-Naltrexone [(+)-NTX], beginning 15 days after intradermal myelin oligodendrocyte glycoprotein (MOG), reverses EAE-related pain in female Dark Agouti rats; no effect on motor scores.

Figure 2.

Female Dark Agouti rats were baselined (BL) for motor scores and for low-threshold mechanical withdrawal thresholds via the von Frey test, followed by intra-dermal low-dose (4 µg) myelin oligodendrocyte glycoprotein (MOG). Allodynia and motor scores were assessed thereafter across the timecourse shown. (+)-NTX (6 mg/kg subcutaneously [SC] 3x/day) vs. saline was initiated on Day 15 post-MOG, continuing through day 30 (see gray rectangle indicating span of drug delivery). Panels A and B: (+)-NTX reversed allodynia, relative to saline control. Main effect of drug: (main effect of drug: left paw: F(1,10) =56.23 p<0.0001; right paw: F(1,10) =55.49 p<0.0001. Panel C: (+)-NTX did not reliably increase motor scores. N=6/group.